Browse > Article

Prognostic Factors of Malignant Pleural Effusion in Non-small Cell Lung Cancer  

Lim, Chang-Young (Department of Thoracic and Cardiovascular Surgery, Bundang CHA General Hospital, College of Medicine, Pochon CHA University)
Lee, Gun (Department of Thoracic and Cardiovascular Surgery, Bundang CHA General Hospital, College of Medicine, Pochon CHA University)
Lee, Hyeon-Jae (Department of Thoracic and Cardiovascular Surgery, Bundang CHA General Hospital, College of Medicine, Pochon CHA University)
Publication Information
Journal of Chest Surgery / v.40, no.2, 2007 , pp. 109-113 More about this Journal
Abstract
Background: In non-small cell lung cancer (NSCLC), malignant pleural effusion is a frequently observed com-plication, and is an important negative prognostic factor. Although many studies concerned to diagnosis and treatment of malignant pleural effusion have been performed, prognostic factors of malignant pleural effusion have rarely been investigated. This study was performed to determine the prognostic factors of malignant pleural effusion n non-small cell lung cancer. Material and Method: We evaluated 33 NSCLC patients with malignant effusion treated between January 2002 and December 2003. We analyzed possible factors: gender, age, TNM Stage, fluid analysis (pH, CEA, LDH, glucose, albumin) and treatment modality. Median survival time of each factor was calculated by Kaplan-Meier method and difference of median survival time between groups of factor compared by log-rank test. The Cox proportional hazards regression model was used to confirm the significance of prognostic factor. Results: Of the 33 patients, 23 (69.7%) patients were adenocarcinoma. The median interval of the diagnosis of lung cancer and malignant effusion was 7.3 months ($25^{th}{\sim}75^{th}:\;3.9{\sim}11.8$), and the median survival time was 3.6 months (95% Confidence Interval: $1.14{\sim}5.99$). In the univariate analysis, using the log-rank test, those with an adenocarcinoma showed a relatively longer median survival time than those of a non-adenocarcinoma (4.067 vs. 1.867 months, p=0.067) without statistical significance. In the multivariate analysis, using the Cox regression, those with a non-adenocarcinoma showed a trend of high risk of cancer death than those with an adenocarcinoma without statistical significance (Relative risk; 2.754, 95% Cl: $0.988{\sim}7.672$, p=0.053). Conclusion: We could not find an independent prognostic factor of malignant pleural effusion in NSCLC. As there was a trend of high risk of cancer death according to histology, further study will be needed.
Keywords
Lung neoplasm; Effusion; Prognosis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Salama G, Miedougue M, Rouxaud P, et al. Evaluation of pleural cypra 21-1 and carcinoembryonic antigen in the diagnosis of malignant pleural effusions. Br J Cancer 1998;77:472-6
2 Villena V, Lopez EA, Echave J, Mart MP, Ortuno B, Estenoz J. Diagnostic value of CA549 in pleural fluid. Comparison with CEA, CA15.3 and CA72.4. Lung Cancer 2003;40:289-94   DOI   PUBMED   ScienceOn
3 Hirsch FR, Franklin WA, Gazdar AF, Bunn PA Jr. Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. Clin Cancer Res 2001;7:5-22   PUBMED
4 Vansteenkiste JF, Paul RDL, Georges JD, et al. Survival and prognostoic factors in resected N2 non-small cell lung cancer: a study of 140 cases. Ann Thorac Surg 1977;63:1441-80   DOI   ScienceOn
5 Niklinski J, Furman M. Clinical tumor markers in lung cancer. Eur J Cancer Prev 1995;4:129-38   DOI   PUBMED   ScienceOn
6 Cohen S, Hossain S. Primary carcinoma of the lung: a review of 417 histologically proved cases. Dis Chest 1966;49:67-73   DOI   PUBMED
7 Johnston WW. The malignant pleural effusion: a review of cytopathologic diagnoses of 584 specimens from 472 consecutive patients. Cancer 1985;56:905-9   DOI   ScienceOn
8 Sugiura S, Ando Y, Minami H, Ando M, Sakai S, Shimokata K. Prognostic value of pleural effusion in patients with non-small cell lung cancer. Clin Cancer Res 1997;3:47-50   PUBMED
9 Hotta K, Segawa Y, Takigawa N, et al. Evaluation of the relationship between serum carcinoembryonic antigen level and treatment outcome in surgically resected clinical stage I patients with non-small cell lung cancer. Cancer Res 2000;20:2177-80
10 Ohta Y, Shimizu Y, Matsumoto I, Watanabe G. Management of malignant effusion by multimodality treatment including the use of paclitaxel administerd by 24-hour intrathoracic infusion for patients with carcinomatous pleuritis. J Exp Clin Cancer Res 2006;25:15-9   PUBMED
11 Sahn SA, Good JTJ. Pleural fluid pH in malignant effusions. diagnostic, prognostic, and therapeutic implications. Ann Intern Med 1988;108:345-9   DOI   PUBMED   ScienceOn
12 Sasaki T, Yasuda H, Nakayama K, et al. Pleurodesis with carboplatin in elderly patients with malignant pleural effusion and lung adenocarcinoma. J Am Geriatr Soc 2006;54:722-3   DOI   PUBMED   ScienceOn
13 Soh J, Toyooka S, Aoe K, et al. Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer. Int J Cancer 2006;119:2353-8   DOI   ScienceOn
14 Good JT, Taryle DA, Shan SA. The pathogenesis of low glucose, low pH malignant effusions. Am Rev Respir Dis 1985;131:737-41   PUBMED